- Home
- HEPS vs NVAX Comparison
HEPS vs NVAX Comparison
Compare HEPS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- NVAX
- Stock Information
- Founded
- HEPS 2000
- NVAX 1987
- Country
- HEPS Turkey
- NVAX United States
- Employees
- HEPS N/A
- NVAX N/A
- Industry
- HEPS Catalog/Specialty Distribution
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HEPS Consumer Discretionary
- NVAX Health Care
- Exchange
- HEPS Nasdaq
- NVAX Nasdaq
- Market Cap
- HEPS 1.1B
- NVAX 1.3B
- IPO Year
- HEPS 2021
- NVAX 1995
- Fundamental
- Price
- HEPS $2.89
- NVAX $6.00
- Analyst Decision
- HEPS
- NVAX Buy
- Analyst Count
- HEPS 0
- NVAX 6
- Target Price
- HEPS N/A
- NVAX $17.83
- AVG Volume (30 Days)
- HEPS 709.6K
- NVAX 6.0M
- Earning Date
- HEPS 06-12-2025
- NVAX 05-09-2025
- Dividend Yield
- HEPS N/A
- NVAX N/A
- EPS Growth
- HEPS N/A
- NVAX N/A
- EPS
- HEPS N/A
- NVAX N/A
- Revenue
- HEPS $1,167,077,294.00
- NVAX $682,162,000.00
- Revenue This Year
- HEPS $43.21
- NVAX $1.07
- Revenue Next Year
- HEPS $37.58
- NVAX N/A
- P/E Ratio
- HEPS N/A
- NVAX N/A
- Revenue Growth
- HEPS 82.39
- NVAX N/A
- 52 Week Low
- HEPS $1.28
- NVAX $3.81
- 52 Week High
- HEPS $4.05
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- HEPS 51.06
- NVAX 41.41
- Support Level
- HEPS $2.52
- NVAX $5.01
- Resistance Level
- HEPS $2.82
- NVAX $6.58
- Average True Range (ATR)
- HEPS 0.14
- NVAX 0.65
- MACD
- HEPS 0.03
- NVAX 0.02
- Stochastic Oscillator
- HEPS 96.00
- NVAX 50.25
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues, and other revenues.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.